Torben Plesner
Impact in
- Hematology top 0.05%
- Multiple Myeloma Research and Treatments
- Platelet Disorders and Treatments
- Blood groups and transfusion
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research
Papers in
- Hematology 132
- Multiple Myeloma Research and Treatments 120
- Immunology 27
- T-cell and B-cell Immunology 15
- Immunodeficiency and Autoimmune Disorders 4
- Co-authors
- Henk M. Lokhorst (19 shared papers)Niels W.C.J. van de Donk (17 shared papers)Amy Kate Sasser (14 shared papers)Tahamtan Ahmadi (16 shared papers)Jean‐Marie Delaissé (15 shared papers)Jakub Krejcik (9 shared papers)Thomas Levin Andersen (8 shared papers)Michael Ploug (4 shared papers)
- Journals
- Blood (45 papers)British Journal of Haematology (13 papers)Scandinavian Journal of Immunology (11 papers)HemaSphere (6 papers)Haematologica (5 papers)
- Partner nations
- DenmarkUnited StatesNetherlands
In The Last Decade
Torben Plesner
193 papers receiving 12.3k citations
Torben Plesner's Hit Papers
Peers
Comparison fields: 5 of 115
- Hematology 8.1k
- Genetics 812
- Geriatrics and Gerontology 215
- Immunology 915
- Oncology 787
Countries citing papers authored by Torben Plesner
This map shows the geographic impact of Torben Plesner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Torben Plesner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Torben Plesner more than expected).
Fields of papers citing papers by Torben Plesner
This network shows the impact of papers produced by Torben Plesner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Torben Plesner. The network helps show where Torben Plesner may publish in the future.
Co-authors
The 25 scholars most cited alongside Torben Plesner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 199 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma Hit paper breakdown → | 2016 | 1206 |
| 2 | Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma Hit paper breakdown → | 2015 | 972 |
| 3 | Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma Hit paper breakdown → | 2016 | 818 |
| 4 | Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma Hit paper breakdown → | 2019 | 783 |
| 5 | Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma Hit paper breakdown → | 2012 | 635 |
| 6 | First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial Hit paper breakdown → | 2016 | 499 |
| 7 | Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma Hit paper breakdown → | 2016 | 360 |
| 8 | Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2019 | 319 |
| 9 | Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial Hit paper breakdown → | 2021 | 276 |
| 10 | 2008 | 262 | |
| 11 | 2012 | 202 | |
| 12 | 2017 | 199 | |
| 13 | 2002 | 198 | |
| 14 | 2018 | 198 | |
| 15 | 2015 | 178 | |
| 16 | 2005 | 170 | |
| 17 | 2013 | 150 | |
| 18 | 2017 | 150 | |
| 19 | 2018 | 146 | |
| 20 | 1997 | 143 |
About Torben Plesner
Torben Plesner is a scholar working on Hematology, Immunology, Genetics, Pathology and Forensic Medicine and Cancer Research, having authored 199 papers that have together received 12.7k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (120 papers), T-cell and B-cell Immunology (15 papers), Chronic Lymphocytic Leukemia Research (13 papers), Lymphoma Diagnosis and Treatment (8 papers), Bone Metabolism and Diseases (7 papers), Protease and Inhibitor Mechanisms (7 papers), Bone health and treatments (6 papers) and Immunodeficiency and Autoimmune Disorders (4 papers). The work is most often cited by research in Hematology (8.1k citations), Genetics (812 citations), Geriatrics and Gerontology (215 citations), Immunology (915 citations) and Oncology (787 citations). Torben Plesner has collaborated with scholars based in Denmark, United States and Netherlands. Frequent co-authors include Henk M. Lokhorst, Niels W.C.J. van de Donk, Amy Kate Sasser, Tahamtan Ahmadi, Jean‐Marie Delaissé, Jakub Krejcik, Thomas Levin Andersen, Michael Ploug, Tineke Casneuf and Brendan M. Weiss. Their work appears in journals such as Blood, British Journal of Haematology, Scandinavian Journal of Immunology, HemaSphere and Haematologica.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.